Behandelresultaat in een 'real-world' cohort van CML patiënten CML artikelen
  1. Behandelresultaat in een 'real-world' cohort van CML patiënten

Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia


Multiple, randomized controlled trials have provided solid evidence for the efficacy and safety of tyrosine kinase inhibitors (TKI) as treatment for chronic myeloid leukemia (CML), but analyses from observational studies, gathered in patients who did not participate in clinical trials (the 'real-world') are scarce. Clinical trials use tight inclusion criteria, strict rules for monitoring and treatment algorithms and may, therefore, not fully reflect results in the general treatment population.1-3 Moreover, randomized controlled trials mainly focus on the outcome of the core study treatment, while some patients will not be able to continue their initial study treatment and are subsequently switched to an alternative treatment outside the trial. (Haematologica 2017 Volume 102(11):1842-1849)

Download het hele artikel